# OnCo record paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025" ;
  schema:name "Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial"@en ;
  schema:description "The 2025 Dutch trial in which eight cycles of FOLFIRINOX before surgery, with no treatment afterwards, gave the same survival (about 22 months) as the older gemcitabine chemoradiotherapy schedule, so either can be used but neither is clearly better."@en ;
  schema:url <https://onco.cc/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(25)00363-8>, <https://pubmed.ncbi.nlm.nih.gov/40945523/>, <https://doi.org/10.1186/s12885-021-08031-z>, <https://doi.org/10.1016/S1470-2045(25)00601-1> ;
  onco:tag "pancreatic-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(25)00363-8> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Janssen QP, van Dam JL, van Bekkum ML, et al." ;
  onco:related <https://onco.cc/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/>, <https://onco.cc/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/>, <https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:institutions <https://onco.cc/institutions/erasmus-mc/>, <https://onco.cc/institutions/amsterdam-umc/> ;
  onco:terms <https://onco.cc/terms/total-neoadjuvant-therapy/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/resectability/> ;
  onco:trials <https://onco.cc/trials/preopanc/> ;
  onco:people <https://onco.cc/people/marc-besselink/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .